Viewing Study NCT00751894



Ignite Creation Date: 2024-05-05 @ 7:52 PM
Last Modification Date: 2024-10-26 @ 9:54 AM
Study NCT ID: NCT00751894
Status: UNKNOWN
Last Update Posted: 2011-01-19
First Post: 2008-09-11

Brief Title: Pegfilgrastim for Stem Cell Mobilization in Children Meg-5
Sponsor: University Hospital Clermont-Ferrand
Organization: University Hospital Clermont-Ferrand

Study Overview

Official Title: Haematopoietic Progenitor Cell Mobilization in Children With Malignancies Evaluation of Pegfilgrastim at 200µgkg After Chemotherapy
Status: UNKNOWN
Status Verified Date: 2011-01
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MEG-5
Brief Summary: Hypothesis pegfilgrastim at 200 µgkg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design phase 2 study Judgment criterion percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis less than 3 blood volume processed
Detailed Description: Patients consecutively referred for HSC mobilization 12 to 18 days after the previous chemotherapy No haematological growth factor during the 8 previous days

Mobilization one sc injection of 200 µgkg pegfilgrastim Neulasta Amgen Evaluation during the study CD34 circulating cells from day 3 to day 7 AE recording Judgment criterion percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis less than 3 blood volume processed Analysis sequential Bayesian study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None